ArticleFrontiers in oncology2026

Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report.

Sultan Aydin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.